At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
Displaying 381–390 of 584 results.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to assess the effectiveness of adding apalutamide, abiraterone acetate, and prednisone to the usual hormone therapy and radiation therapy for patients who have a recurrence of their prostate cancer after surgery (prostatectomy). Specifically, there must have been cancer originally found in the lymph nodes at the time of surgery for patients to be eligible for this study. The treatment being evaluated is a "salvage therapy" for recurrent prostate cancer. Patients will be randomly assigned to receive hormone therapy and radiation therapy after prostate cancer surgery with or without apalutamide, abiraterone acetate, and prednisone. 
-
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
-
A Phase 1B Study of Gilteritinib Plus Ivosidenib or Enasidenib in People With Acute Myeloid LeukemiaIn this study, researchers want to find the best doses of 2 different drug combinations. This study is for people with acute myeloid leukemia (AML) that keeps growing even after treatment. You also must have changes (mutations or variants) in the FLT3 gene, and in either the IDH1 or IDH2 genes. The FLT3 gene can cause cancer cells to grow. The IDH1 and IDH2 genes cause low blood cell counts.
-
The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.
-
Researchers want to find the best doses of BNT324 and BNT327 when given together to treat lung cancer. The people in this study have lung cancer that spread and came back or got worse after treatment.
-
This study is comparing the effectiveness of combination chemotherapy plus tucatinib and trastuzumab versus combination chemotherapy alone in people with metastatic colorectal cancer that is positive for the HER2 protein. The combination chemotherapy is called mFOLFOX6 (oxaliplatin, leucovorin or levoleucovorin, and fluorouracil) and it is a standard treatment for advanced colorectal cancer.
-
Normally when people have B-cell lymphoma that is not in complete remission, they do not immediately have another treatment. They have observation. That means their doctor closely monitors their disease with imaging tests to see if their disease is improving or worsening. If their disease gets worse, they may receive more treatment.
-
In this study, researchers are assessing the safety and effectiveness of using the drug ruxolitinib in patients with T-cell lymphoma or natural killer (NK)-cell lymphoma that has come back or continued to grow despite prior treatment. Ruxolitinib is already approved for treating a bone marrow disease called myelofibrosis. It works by inhibiting a protein called JAK, which works with another protein called STAT to promote the growth of many T-cell and NK-cell lymphomas. By blocking JAK, ruxolitinib may cause lymphomas to shrink.